Compare Stocks: SLDB, ELVN, LEGN, and RLAY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$59.32 -0.6%	$55.66	$14.78 ▼ $62.32	$4.35B	0.3	790,280 shs	1.11 million shs
LEGN Legend Biotech	$21.52 -1.1%	$22.72	$16.24 ▼ $37.50	$4.17B	0.4	2.08 million shs	811,970 shs
RLAY Relay Therapeutics	$19.04 +0.2%	$19.36	$3.86 ▼ $21.27	$4.17B	1.69	2.38 million shs	2.05 million shs
SLDB Solid Biosciences	$10.25 -1.6%	$9.34	$3.79 ▼ $11.45	$1.10B	2.44	866,481 shs	495,297 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	0.00%	+2.52%	-1.58%	+70.90%	+183.15%
LEGN Legend Biotech	0.00%	+8.25%	+11.62%	-34.03%	-40.14%
RLAY Relay Therapeutics	0.00%	+1.44%	-3.59%	+40.83%	+363.26%
SLDB Solid Biosciences	0.00%	+4.91%	+17.68%	+52.99%	+78.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$59.32 -0.6%	$55.66	$14.78 ▼ $62.32	$4.35B	0.3	790,280 shs	1.11 million shs
LEGN Legend Biotech	$21.52 -1.1%	$22.72	$16.24 ▼ $37.50	$4.17B	0.4	2.08 million shs	811,970 shs
RLAY Relay Therapeutics	$19.04 +0.2%	$19.36	$3.86 ▼ $21.27	$4.17B	1.69	2.38 million shs	2.05 million shs
SLDB Solid Biosciences	$10.25 -1.6%	$9.34	$3.79 ▼ $11.45	$1.10B	2.44	866,481 shs	495,297 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	0.00%	+2.52%	-1.58%	+70.90%	+183.15%
LEGN Legend Biotech	0.00%	+8.25%	+11.62%	-34.03%	-40.14%
RLAY Relay Therapeutics	0.00%	+1.44%	-3.59%	+40.83%	+363.26%
SLDB Solid Biosciences	0.00%	+4.91%	+17.68%	+52.99%	+78.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	26.43% Upside
LEGN Legend Biotech	2.47	Hold	$53.43	148.27% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	36.12% Upside
SLDB Solid Biosciences	2.83	Moderate Buy	$18.18	77.38% Upside

Current Analyst Ratings Breakdown

Latest SLDB, ELVN, LEGN, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $26.00
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$12.22 per share	N/A
LEGN Legend Biotech	$1.03B	4.05	N/A	N/A	$6.35 per share	3.39
RLAY Relay Therapeutics	$15.35M	271.82	N/A	N/A	$4.06 per share	4.69
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	18.39	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest SLDB, ELVN, LEGN, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	64.07	64.07
LEGN Legend Biotech	N/A	3.04	2.94
RLAY Relay Therapeutics	N/A	18.27	18.27
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
LEGN Legend Biotech	70.89%
RLAY Relay Therapeutics	96.98%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	3.00%
LEGN Legend Biotech	0.02%
RLAY Relay Therapeutics	5.04%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	73.27 million	71.07 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
RLAY Relay Therapeutics	330	219.14 million	208.10 million	Optionable
SLDB Solid Biosciences	100	107.22 million	104.37 million	Optionable

SLDB, ELVN, LEGN, and RLAY Headlines

Recent News About These Companies

Solid Biosciences to Participate at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Cantor Fitzgerald Raises Solid Biosciences (NASDAQ:SLDB) Price Target to $26.00

August 29, 2026 | americanbankingnews.com

Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $26.00 at Cantor Fitzgerald

August 27, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Trading 5.5% Higher - Should You Buy?

August 25, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial

August 21, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7% - Time to Sell?

August 20, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 20, 2026 | marketbeat.com

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB

August 11, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

June 1, 2026 | globenewswire.com

J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

May 24, 2026 | theglobeandmail.com

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

May 20, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)

May 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, ELVN, LEGN, and RLAY Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$59.32 -0.33 (-0.55%)

As of 09/4/2026 04:00 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Legend Biotech NASDAQ:LEGN

$21.52 -0.23 (-1.06%)

As of 09/4/2026 04:00 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Relay Therapeutics NASDAQ:RLAY

$19.04 +0.03 (+0.16%)

As of 09/4/2026 04:00 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$10.25 -0.17 (-1.63%)

As of 09/4/2026 04:00 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLDB, ELVN, LEGN, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLDB, ELVN, LEGN, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLDB, ELVN, LEGN, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, ELVN, LEGN, and RLAY Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLDB, ELVN, LEGN, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLDB, ELVN, LEGN, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLDB, ELVN, LEGN, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, ELVN, LEGN, and RLAY Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools